Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research
DURHAM, N.C.--(BUSINESS WIRE)--Nov 6, 2023--<a ...
DURHAM, N.C.--(BUSINESS WIRE)--Nov 6, 2023--<a ...
PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ -- Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets will present multispecific molecules targeting GPRC5D, BCMA, and CD3 this week during the Society for Immunotherapy of Cancer (SITC) ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 3, 2023--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for ...
PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&l=en&o=4013368-1&h=1366167913&u=http%3A%2F%2Fwww.verismotherapeutics.com%2F&a=Verismo+Therapeutics">Verismo Therapeutics</a>, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 3, 2023--Ankyra Therapeutics, an emerging clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced data from a preclinical study using ANK-101, an IL-12 anchored therapeutic, in combination with cytotoxic ...
DUBLIN--(BUSINESS WIRE)--Nov 3, 2023--The <a ...